An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)

Mark M. Awad, Quincy S.C. Chu, Leena Gandhi, Joe J. Stephenson, Ramaswamy Govindan, Daniel S. Bradford, Philip D. Bonomi, David M. Ellison, Keith D. Eaton, Holger Fritsch, Gerd Munzert, Bruce E. Johnson, Mark A. Socinski

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Objectives This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed small cell lung cancer (SCLC). Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response, and safety. Materials and methods Patients were treated with the recommended phase II dose of 200 mg of BI 2536 intravenously every 21 days. This was a two-stage design with an early stopping rule in place if responses were not seen in at least 2 of the first 18 enrolled patients. Results and conclusion Twenty-three patients were enrolled in the study and 21 patients were evaluable for response. No responses were observed and all 23 patients have progressed. The median PFS was 1.4 months. Treatment was generally well tolerated and the most frequent adverse events were neutropenia, fatigue, nausea, vomiting, and constipation. BI 2536 is not effective in the treatment of sensitive relapsed SCLC. The criteria for expanding the trial to the second stage were not achieved, and the study was terminated for a lack of efficacy.

Original languageEnglish
Pages (from-to)126-130
Number of pages5
JournalLung Cancer
Volume104
DOIs
StatePublished - Feb 1 2017

Keywords

  • BI 2536
  • Plk-1 inhibition
  • Polo-like kinase
  • Small cell lung cancer

Fingerprint

Dive into the research topics of 'An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)'. Together they form a unique fingerprint.

Cite this